{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Indolent+B-cell+Lymphomas&page=7", "query": { "condition": "Indolent B-cell Lymphomas", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 160, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Indolent+B-cell+Lymphomas&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Indolent+B-cell+Lymphomas&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T05:03:54.944Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)", "Non Hodgkin Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Zandelisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "CHOP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2021-08-13", "completion_date": "2023-03-20", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 14, "location_summary": "Tucson, Arizona • Fountain Valley, California • Long Beach, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745832" }, { "nct_id": "NCT02376699", "title": "Safety Study of SEA-CD40 in Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Squamous Cell", "Hodgkin Disease", "Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Follicular", "Lymphoma, Large B-Cell, Diffuse", "Melanoma", "Neoplasm Metastasis", "Neoplasms, Head and Neck", "Neoplasms, Squamous Cell", "Non-Small Cell Lung Cancer", "Non-Small Cell Lung Cancer Metastatic", "Non-small Cell Carcinoma", "Squamous Cell Cancer", "Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Squamous Cell Neoplasm", "Lymphoma, Non-Hodgkin", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Intravenous (IV) SEA-CD40", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Subcutaneous (SC) SEA-CD40", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2015-02-28", "completion_date": "2023-04-14", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02376699" }, { "nct_id": "NCT03498612", "title": "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-07-09", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03498612" }, { "nct_id": "NCT06860880", "title": "Combating Cancer-Related Fatigue: A Personalized Supportive Care Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Indolent Lymphomas", "Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom Macroglobulinemia", "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Exercise", "type": "OTHER" }, { "name": "Diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-06-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06860880" }, { "nct_id": "NCT06784726", "title": "Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Odronextamab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-09-04", "completion_date": "2033-04-11", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784726" }, { "nct_id": "NCT04323956", "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Indolent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2020-06-15", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04323956" }, { "nct_id": "NCT00068315", "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hematopoietic/Lymphoid Cancer", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 7, "location_summary": "Canton, Ohio • Cleveland, Ohio • Middleburg Heights, Ohio + 3 more", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Middleburg Heights", "state": "Ohio" }, { "city": "Orange", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068315" }, { "nct_id": "NCT03144674", "title": "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2017-12-18", "completion_date": "2024-05-29", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Tempe, Arizona • Redondo Beach, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144674" }, { "nct_id": "NCT05458297", "title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Follicular Lymphoma", "Richter Transformation Lymphoma" ], "interventions": [ { "name": "Zilovertamab vedotin", "type": "BIOLOGICAL" }, { "name": "Nemtabrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2022-07-21", "completion_date": "2029-05-17", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 20, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Decatur", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458297" }, { "nct_id": "NCT02367040", "title": "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma,Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (Aliqopa, BAY80-6946)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 458, "start_date": "2015-08-03", "completion_date": "2024-11-15", "has_results": true, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-21T05:03:54.944Z", "location_count": 16, "location_summary": "West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more", "locations": [ { "city": "West Covina", "state": "California" }, { "city": "Ashland", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367040" } ] }